Celgene Further Commits To Neuroscience With Prothena Pact
Executive Summary
It is a risky business but the biotech major is paying $150m upfront, and potentially hundreds of millions of dollars more, to work with Prothena and develop therapies targeted at proteins implicated in highly challenging neurodegenerative diseases such as Alzheimer's and ALS.
You may also be interested in...
Biopharma Quarterly Dealmaking Statistics, Q1 2018
Biopharma financing started the year solidly with $16.6 billion in total deal value, a 14% increase over the previous quarter. Q1 2018 biopharma merger and acquisition deal value, led by Cigna's $67 billion buy of Express Scripts, topped even the previous all-time-high set in Q4 2107, while alliances totaled $30.7 billion and featured big oncology and neurology partnerships.
Deal Watch Asia Focus: Pfenex Licenses Asian Rights To Forteo Copy To NT Pharma Group
Otsuka obtains Japanese rights to two cancer gene therapy candidates from Takara. GlaxoSmithKline extends its protein degradation collaboration with Kymera.
Celgene's Terrie Curran On Building, Broadening The I&I Franchise
Celgene has hit multiple roadblocks in building its inflammation and immunology (I&I) portfolio, but it has a lot of potential shots on goal to eventually help the company diversify its revenue beyond the cancer blockbuster Revlimid, starting with flagship product Otezla.